Aglaia is an oncology specialist investor which selects and matures early-stage breakthrough inventions that have the potential to transform cancer prevention, diagnosis and therapy.
Employees: 1-10
Investment Stage: Pre-Seed; Seed; Series A
Portfolio 11
| Date | Name | Website | Total Raised | Location |
| - | Merus N.V. | merus.nl | $157.12M | Netherland... |
| - | Modra Phar... | modrapharmaceuticals.com | - | Netherland... |
| - | MIMETAS - ... | mimetas.com | $25.2M | Netherland... |
| - | Macrophage... | macrophagepharma.com | - | United Kin... |
| - | Cristal Th... | cristaltherapeutics.com | $21.11M | Netherland... |
| - | ISA Pharma... | isa-pharma.com | $30.78M | Netherland... |
| - | InteRNA Te... | interna-technologies.com | $32.92M | - |
| - | Synthon | synthon.com | - | Netherland... |
| - | Inthera | intherabio.com | $16.38M | - |
| - | Sapreme Te... | sapreme-technologies.com | $17.35M | Netherland... |
Show more
Persons 6
| Date | First Name | Last Name | Title | Location | |||
| - | Mark | Krul | - | linkedin.c... | - | k**l@aglai... | - |
| - | Eric | van der Pu... | - | linkedin.c... | - | e**p@aglai... | - |
| - | Karl | Rothweiler | - | - | k*r@aglaia... | - | |
| - | Folkert | van Cleef | - | linkedin.c... | - | f*c@aglaia... | - |
| - | Angelique | Hermeling | - | linkedin.c... | - | a*h@aglaia... | - |
| - | Ernst | Geutjes | - | linkedin.c... | - | i**o@aglai... | - |
Mentions in press and media 2
| Date | Title | Description |
| 12.04.2022 | Bpifrance backs Ribonexus with €2 million to develop melanoma treatment | French biotechnology startup Ribonexus has raised €2 million in funding from the French public investment bank Bpifrance as part of the ‘Deeptech Plan’ of the French government. The extra capital will enable the firm to develop new therapie... |
| - | Bpifrance backs Ribonexus with €2 million to develop melanoma treatment | French biotechnology startup Ribonexus has raised €2 million in funding from the French public investment bank Bpifrance as part of the ‘Deeptech Plan’ of the French government. The extra capital will enable the firm to develop new therapie... |